Ivermectin B1a

Ivermectin B1a, a derivative of Avermectin B1a (HY-15308), is a main component of Ivermectin (HY-15310)[1]. Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19[2].

Research Areas >> Infection

Signaling Pathways >> Anti-infection >> SARS-CoV

Ivermectin belongs to the macrocyclic lactone class of avermectins and consists of a mixture of two homologous compounds, ivermectin B1a (not less than 80%) and ivermectin B1b (not more than 20%). Ivermectin B1a, the major component of Ivermectin, is inactive at a concentration of 0.3 μg/ml, whereas in the case of the minor component, ivermectin B1b, the same concentration produces 100% mortality of snails[1].

[1]. Naftale Kat, et al. Ivermectin Efficacy Against Biomphalaria, Intermediate Host Snail Vectors of Schistosomiasis. J Antibiot (Tokyo). 2017 May;70(5):680-684.

[2]. Khan Sharun, et al. Ivermectin, a New Candidate Therapeutic Against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 2020 May 30;19(1):23.